Quantcast

Cryo-Cell’s New Cord Blood Processing Method Enables Parents to Obtain Better Cord Blood Units for Their Babies

April 22, 2014

(OTCQB:CCEL) Cryo-Cell International, Inc., the world’s first cord blood bank, announced today that parents are able to obtain better cord blood units for their babies through a new advanced processing technology. Cryo-Cell becomes the first nationwide private cord blood bank to license the new PrepaCyte CB technology from Pall Corporation (NYSE:PLL).

Oldsmar, FL (PRWEB) April 22, 2014

New PrepaCyte® CB cord blood processing technology improves viable stem cell recovery and removes 99% of red blood cell contaminants.

“As a parent who has had the opportunity to carefully evaluate all commercial processing methods available, I believe that Cryo-Cell obtains the best cord blood units on the market today. Cryo-Cell continues to lead the industry in quality because we are dedicated to offering the industry’s premier cord blood banking service as demonstrated by the fact that Cryo-Cell has more independent, quality-related certifications than any other cord blood bank,” stated David Portnoy, Chairman and Co-CEO of Cryo-Cell.

PrepaCyte CB offers cord blood banks a simple and efficient method of improving healthy stem cell recovery while removing 99% of red blood cell contaminants.

“Cryo-Cell has been a leader in the cord blood banking industry for 25 years. We are delighted to partner with Cryo-Cell as it continues to raise the bar in family cord blood banking,” said Vincent Guercio, Director of Pall Medical Cell Therapy.

Added Linda Kelley, PhD, Chief Scientific Officer of Cryo-Cell, “Cryo-Cell is committed to adopting best practices as the cord blood field evolves, including new processing methods that yield better outcomes for families. Processing samples for family banking requires maximizing cell yields, which can best be done by putting the most advanced technology available in the hands of highly trained technologists who scrutinize every sample individually. Cryo-Cell is proud to be at the leading edge.”

About Cryo-Cell International

Founded in 1989, Cryo-Cell International, Inc. is the world's first private cord blood bank. More than 500,000 parents from 87 countries trust Cryo-Cell to preserve their family members' stem cells. Cryo-Cell's mission is to provide clients with state-of-the-art stem cell cryopreservation services and support the advancement of regenerative medicine. Cryo-Cell operates in a facility that is compliant with Good Manufacturing Practice and Good Tissue Practice (cGMP/cGTP), and is ISO 9001:2008 certified and accredited by the American Association of Blood Banks. Cryo-Cell is a publicly traded company, OTCQB: CCEL. For more information, please visit http://www.cryo-cell.com. You may also follow Cryo-Cell on Facebook and Twitter.

About Pall Corporation

Pall Corporation (NYSE:PLL) is a filtration, separation and purification leader providing solutions to meet the critical fluid management needs of customers across the broad spectrum of life sciences and industry. Pall works with customers to advance health, safety and environmentally responsible technologies. The Company’s engineered products enable process and product innovation and minimize emissions and waste. Pall Corporation is an S&P 500 company serving customers worldwide. Follow us on Twitter @PallCorporation or visit http://www.pall.com.

For the original version on PRWeb visit: http://www.prweb.com/releases/2014/04/prweb11775503.htm


Source: prweb



comments powered by Disqus